HLA等位基因与PLA2R相关膜性肾病的预后
该前瞻性队列纳入392例中国PLA2R相关膜性肾病患者,对5个HLA基因进行分型。研究发现携带DRB1*13:01/DQB1*06:03、DRB1*04:05或DQB1*03:02任一风险等位基因者,随访期间eGFR下降≥40%的风险显著升高,且多变量校正后仍独立相关。
要点
- DRB1*13:01、DQB1*06:03、DRB1*04:05、DQB1*03:02与eGFR下降≥40%风险相关。
- 携带任一风险等位基因者风险比为3.9(95%CI 2.3–6.7),校正后为4.1(95%CI 2.3–7.1)。
核心结论
- 携带DRB1*13:01/DQB1*06:03、DRB1*04:05或DQB1*03:02任一HLA等位基因,与中国PLA2R相关膜性肾病患者的不良肾脏预后独立相关。
研究设计与样本
- 前瞻性队列研究,纳入392例PLA2R相关膜性肾病患者,对DRB1、DQA1、DQB1、DRB3和DRB5五个HLA基因进行分型。
主要发现
- 共鉴定79个HLA等位基因。
- DRB1*13:01(n=12)与eGFR下降≥40%相关,HR 3.7(95%CI 1.8–7.8),P<0.001。
- DQB1*06:03(n=12)与eGFR下降≥40%相关,HR 3.7(95%CI 1.8–7.8),P<0.001。
- DRB1*04:05(n=12)与eGFR下降≥40%相关,HR 3.8(95%CI 1.5–9.5),P=0.004。
- DQB1*03:02(n=21)与eGFR下降≥40%相关,HR 3.1(95%CI 1.4–6.7),P=0.005。
关键数值与推荐
- 校正年龄、性别、蛋白尿、白蛋白、eGFR和抗PLA2R抗体水平后,携带任一风险等位基因仍与eGFR下降≥40%风险升高相关,HR 4.1(95%CI 2.3–7.1),P<0.001。
临床怎么用
- 对PLA2R相关膜性肾病患者可考虑HLA分型检测,携带风险等位基因者提示预后较差,需更密切监测肾功能。
局限性
- 研究人群为中国患者,结论外推需谨慎;部分风险等位基因携带者样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Associations between HLA alleles and susceptibility to M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy have been well defined previously in Chinese patients. However, the relationships between HLA alleles and kidney outcome remain unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five HLA genes (DRB1, DQA1, DQB1, DRB3, and DRB5) were genotyped in a prospective cohort of 392 patients with PLA2R-related membranous nephropathy. The associations between HLA alleles and kidney outcomes were studied. RESULTS: A total of 79 HLA alleles were identified in this study. Four HLA alleles, DRB1*13:01 (n=12; hazard ratio, 3.7; 95% confidence interval, 1.8 to 7.8; P<0.001), DQB1*06:03 (n=12; hazard ratio, 3.7; 95% confidence interval, 1.8 to 7.8; P<0.001), DRB1*04:05 (n=12; hazard ratio, 3.8; 95% confidence interval, 1.5 to 9.5; P=0.004), and DQB1*03:02 (n=21; hazard ratio, 3.1; 95% confidence interval, 1.4 to 6.7; P=0.005), were associated with a ≥40% eGFR decline during follow-up. DRB1*13:01 and DQB1*06:03 were tightly linked with each other. Forty-four of the 392 patients (11%) carried at least one of the four identified risk HLA alleles in this study. Compared with patients who were negative for all risk HLA alleles, those carrying at least one risk HLA allele had a significant risk of a ≥40% eGFR decline during follow-up (hazard ratio, 3.9; 95% confidence interval, 2.3 to 6.7; P<0.001). After adjusting for age, sex, proteinuria, albumin, eGFR, and anti-PLA2R antibody levels, multivariable Cox analysis showed that patients carrying any of the four risk HLA alleles remained associated with a higher risk of a ≥40% decline in eGFR (hazard ratio, 4.1; 95% confidence interval, 2.3 to 7.1; P<0.001). CONCLUSIONS: Carrying any of the HLA alleles, DRB1*13:01/DQB1*06:03, DRB1*04:05, and DQB1*03:02, was independently associated with poor prognosis in Chinese patients with PLA2R-related membranous nephropathy.
引用
- Le WB, Shi JS, Fan Y, et al. HLA Alleles and Prognosis of PLA2R-Related Membranous Nephropathy. Clin J Am Soc Nephrol. 2021. PMID: 34083219. doi:10.2215/CJN.18021120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。